The invention described herein relates to methods and compositions for treatment of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity), or inhibition of inflammation and/or immune response in the intestine due to antigenic food peptides, by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.

The present invention provides compositions comprising Trabectedin or a tTF-NGR protein for use in the treatment of cancer in an individual, wherein the treatment comprises the following steps: (a) administering to the individual an effective amount of a composition comprising Trabectedin, and (b) subsequently administering to the individual an effective amount of a composition comprising a tTF-NGR protein.

Compositions are disclosed herein that include an extracellular matrix (ECM) hydrogel and matrix bound nanovesicles (MBV). These compositions provide a synergistic effect and are of use for treating subjects.

The present invention relates to a compound for use in the treatment or prevention of a liver disease, wherein the compound is a amyloid beta related protein, the amyloid beta related protein being selected from the group consisting of amyloid beta protein, a amyloid beta peptide derived therefrom, amyloid precursor protein (APP), a compound involved in the generation of an amyloid beta peptide from APP, or a compound inhibiting the degradation of the amyloid beta protein or of amyloid peptides derived therefrom.

The present invention provides a novel proteolytic enzyme composition more particularly an orally administered proteolytic enzyme composition comprising of one or more acid proteases, one or more alkaline protease and one or more plant proteases. More particularly, the composition comprises of microbial (fungal, bacterial or other microbes) protease enzymes, proteases from plant and animals proteases thereof.

The present invention provides a novel proteolytic enzyme composition more particularly an orally administered proteolytic enzyme composition comprising of one or more acid proteases, one or more alkaline protease and one or more plant proteases. More particularly, the composition comprises of microbial (fungal, bacterial or other microbes) protease enzymes, proteases from plant and animals proteases thereof.

Described herein are methods of identifying a mammal having a neurological disease or disorder, such as AD or MCI, or at risk for developing a neurological disease or disorder, such as AD or MCI. Provided herein are also methods of monitoring the progression of a neurological disease or disorder in a patient or monitoring the effectiveness of therapeutic agent or treatment of a patient having a neurological disease or disorder.

Disclosed are methods of treating metabolic diseases, such as non-alcoholic fatty liver disease (NAFLD), including nonalcoholic steatohepatitis (NASH), and Type II diabetes. In some examples, the method includes administration of an effective amount of a (pro)renin receptor (PRR) antagonist to a subject in need thereof, such as a patient at risk of acquiring or afflicted with NAFLD, NASH and/or Type II diabetes, to prevent, inhibit, and/or reduce one or more signs or symptoms associated with NAFLD, NASH and/or Type II diabetes, such as by reducing the severity of liver steatosis.

A therapeutic composition for the treatment of the symptoms of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, and the method for preparing the therapeutic agents is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as an indicator of the presence of neurological and mental health disorders, such as Alzheimer's disease, bipolar disorder, obsessive compulsive disorder, and oppositional defiant disorder, or the likelihood of an individual to develop these disorders is disclosed.

The invention described herein relates to methods and compositions for treatment of gluten intolerance and related conditions (e.g., celiac disease and gluten sensitivity), or inhibition of inflammation and/or immune response in the intestine due to antigenic food peptides, by administration of a pharmaceutical composition comprising one or more Nepenthes enzymes.